Biodegradable polymer Biolimus-eluting stent (Nobori®) for the treatment of coronary artery lesions: review of concept and clinical results

Figures & data

Figure 1 The Biolimus-eluting stent (Nobori®; Terumo Corporation, Tokyo, Japan): chemical structure of Biolimus A9 and stent design. Replacement of hydrogen by alkoxy-alkyl group at 40-O position increases its lipophilicity.

Table 1 Characteristics and principal results of recent trials with the Nobori® (Terumo Corporation, Tokyo, Japan) stent as compared with first- and second-generation DESs

Trial	Date	Number of patients	Design of the study and comparator	Longer follow-up available and results
NOBORI CORE^Citation54	2008	43 Stable angina 100%	Prospective, multicenter, and comparative. Vasomotion study after implantation of a BES Nobori® stent and an SES	Nine months follow-up. Endothelium-dependent vasomotion is preserved after BES implantation as compared with SES and may reduce thrombotic events.
NOBORI I^Citation57	2009	243 UA 28% Stable angina 72%	RCT BES Nobori® stent versus PES Taxus® Liberté	Nine months follow-up. Nobori® stent showed greater degree of neointimal hyperplasia inhibition. Reduction of ISR. No ST up to 9 months.
SORT OUT V^Citation59	2013	2,458 STEMI 18% NSTEMI and UA 30% Stable angina 52%	RCT BES Nobori® stent versus first-generation SES Cypher® stent to treat coronary artery stenosis	Twelve months follow-up. BES did not show non-inferiority and did not improve clinical outcomes when compared with SES. Higher early ST in the BES group.
COMPARE II^Citation60	2013	2,707 STEMI 22% NSTEMI 27% UA 10% Stable angina 41%	RCT BES Nobori® stent versus second-generation EES Xience® or Prime®	At 12 months follow-up, BES Nobori® stent showed non-inferiority as compared with EES. Procedural failure higher in the BES group.
NEXT^Citation61	2013	3,235 STEMI and NSTEMI 5% UA 12% Stable angina 83%	RCT BES Nobori® stent as compared with EES Xience® or Prime®	Twelve months follow-up. Outcome after implantation of BES is non-inferior to EES, with very low rate of ST.

Abbreviations: BES, biolimus-eluting stent; DES, drug-eluting stent; EES, everolimus-eluting stent; ISR, in-stent restenosis; NSTEMI, non-ST-segment elevation myocardial infarction; PES, paclitaxel-eluting stent; RCT, randomized clinical trial; SES, sirolimus-eluting stent; ST, stent thrombosis; STEMI, ST-segment elevation myocardial infarction; UA, unstable angina.

OstojicMSagicDBeleslinBFirst clinical comparison of Nobori Biolimus A9 eluting stents with Cypher sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomesEuroIntervention2008357457919608483

 PubMedGoogle Scholar

ChevalierBSilberSParkS-JRandomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial – phase 2Circ Cardiovasc Interv2009218819520031715

 PubMed Web of Science ®Google Scholar

ChristiansenEHJensenLOThayssenPScandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) V investigatorsBiolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT-OUT V): a randomized non-inferiority trialLancet201338166166923374649

 PubMed Web of Science ®Google Scholar

SmitsPCHofmaSTogniMAbluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomized, controlled, non-inferiority trialLancet201338165166023374650

 PubMed Web of Science ®Google Scholar

NatsuakiMKozumaKMorimotoTNEXT InvestigatorsBiodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trialJ Am Coll Cardiol20136218119023684673

 PubMed Web of Science ®Google Scholar